43P - Integrated analysis of genome-wide DNA methylation and gene expression profiles identifies potential novel biomarkers of rectal cancer

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Rectal Cancer
Translational Research
Presenter Guodong Li
Citation Annals of Oncology (2016) 27 (suppl_9): ix9-ix18. 10.1093/annonc/mdw574
Authors G. Li, J. Wei, S. Dang, Y. Zhou, X. Li, H. Chen, M. Liu
  • Department Of General Surgery, Fourth Hospital of Harbin Medical University, 150001 - Harbin/CN

Abstract

Background

DNA methylation was regarded as the promising biomarker for rectal cancer diagnosis. However, the optimal methylation biomarkers with ideal diagnostic performance for rectal cancer are still limited. This study was aimed to identify new molecular markers for rectal cancer.

Methods

We mapped DNA methylation and transcriptomic profiles in the six rectal cancer and paired normal samples. Further analysis revealed the hypermethylated probes in cancer prone to be located in gene promoter.

Results

Transcriptome analysis presented 773 low-expressed and 1,161 over-expressed genes in rectal cancer. Correction analysis identified a panel of 36 genes with an inverse correlation between methylation and gene expression levels, including 10 known colorectal cancer related genes. From the other 26 novel mark genes, GFRA1 and GSTM2 were selected for further analysis on the basis of their biological functions. Further experiment analysis confirmed their methylation and expression status in a larger number (44) of rectal cancer samples, and ROC curves showed higher AUC than SEPT9, which has been used as a biomarker in rectal cancer.

Conclusions

Our data suggests that aberrant DNA methylation of contiguous CpG sites in methylation array may be potential prognostic markers of rectal cancer.

Clinical trial indentification

Legal entity responsible for the study

Ming Liu

Funding

National Natural Science Foundation of China Grant number: 81372612, 81302059

Disclosure

All authors have declared no conflicts of interest.